Mainland China’s regulatory evolution brings greater access to novel drugs
Clarivate
MAY 11, 2023
To address this pain point, the Center for Drug Evaluation (CDE) announced in 2017 that it would accept marketing applications based on clinical evidence generated in multicenter studies conducted overseas [1]. However, to gain approval for a new drug or label expansion, developers needed to meet specific requirements laid out by the CDE.
52 
Let's personalize your content